Trillium Therapeutics registers $57.5 million of stock for public sale

Bookrunners Leerink Partners, Cowen help fund development of SIRPaFc

By Devika Patel

Knoxville, Tenn., March 11 – Trillium Therapeutics Inc. will conduct a public sale of common stock with a 30-day greenshoe, according to a Form F-1 filed Wednesday with the Securities and Exchange Commission. The company has registered up to $57.5 million of stock.

Leerink Partners and Cowen and Co. are the bookrunning managers.

Proceeds will be used for the development of SIRPaFc, working capital and other general corporate purposes.

The immuno-oncology company is based in Toronto.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.